Main Article Content
Abstract
The hepatitis C virus (HCV) was identified in 1989 by Michael Houghton and was considered to be the origin of most of the so-called non-A non-B1,2 hepatitis. Today, it is a major public health problem worldwide given its high prevalence and high evolution towards chronicity, becoming one of the main causes of liver transplantation3. The incidence and prevalence of HCV infection among haemodialysis patients is often higher than in the general population4. Although in-hospital infection control has improved thanks to multiple lines of research aimed at optimizing biosecurity measures, the high risk of progressive liver damage, cirrhosis, liver failure or hepatocellular carcinoma, make this virus a challenge for health policies5.
Keywords
Article Details
Author copyright notice
© Authors grant the publisher the non-exclusive licence to publish the work and consent to its use and distribution under the Creative Commons Attribution - NonCommercial 4.0 International (CC BY-NC 4.0) licence. Read the licensing information and the legal text here. This must be expressly stated wherever necessary.